Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes

BACKGROUND: The reshaping of the immune landscape by nivolumab (NIVO) and ipilimumab (IPI) and its relation to patient outcomes is not well described. METHODS: We used high-parameter flow cytometry and a computational platform, CytoBrute, to define immunophenotypes of up to 15 markers to assess peri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Woods, David M., Laino, Andressa S., Winters, Aidan, Alexandre, Jason, Freeman, Daniel, Rao, Vinay, Adavani, Santi S., Weber, Jeffery S., Chattopadhyay, Pratip K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7308045/
https://ncbi.nlm.nih.gov/pubmed/32369447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.137066
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados